Europe Afatinib Market Size, Share, Growth, and Industry Analysis, By Drug Formulation (Tablets, Capsules, Injectable), By Application (Non-Small Cell Lung Cancer, Metastatic Lung Cancer, EGFR Mutation Therapy), Regional Insights and Forecast to 2034

Table of Contents

1. Executive Summary
   1. Introduction
2. Market Introduction
   1. Market Definition
   2. Scope of the Study
   3. Market Structure
3. Research Methodology
   1. Primary Research
   2. Research Methodology
   3. Assumptions & Exclusions
   4. Secondary Data Sources
4. Market Factor Analysis
   1. Value Chain Analysis: Europe Afatinib Market
   2. Porters Five Forces Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitution
      4. Threat of New Entrants
      5. Competitive Rivalry
5. Market Dynamics
   1. Drivers
   2. Restraints
   3. Opportunities
6. Recent Trends Analysis
7. Impact of COVID-19 on Europe Afatinib Market
   1. Pre and Post Covid -19 Market Scenario Analysis
   2. Market Recovery Timeline and Challenge
   3. Measures Taken by Top Players
8. Regulatory Landscape
9. Europe Afatinib Market, Drug Formulation
   1. Introduction
      1. Market Size and Forecast, Drug Formulation
   2. Tablets
      1. Market Size and Forecast, By Region
   3. Capsules
      1. Market Size and Forecast, By Region
   4. Injectable
      1. Market Size and Forecast, By Region
10. Europe Afatinib Market, Application
    1. Introduction
       1. Market Size and Forecast, Application
    2. Non-Small Cell Lung Cancer
       1. Market Size and Forecast, By Region
    3. Metastatic Lung Cancer
       1. Market Size and Forecast, By Region
    4. EGFR Mutation Therapy
       1. Market Size and Forecast, By Region
11. Regional Overview
    1. Introduction
       1. Market Size and Forecast
    2. Europe
       1. Market Size and Forecast
          1. Drug Formulation
             1. Tablets
             2. Capsules
             3. Injectable
          2. Application
             1. Non-Small Cell Lung Cancer
             2. Metastatic Lung Cancer
             3. EGFR Mutation Therapy
       2. U.K.
          1. Drug Formulation
             1. Tablets
             2. Capsules
             3. Injectable
          2. Application
             1. Non-Small Cell Lung Cancer
             2. Metastatic Lung Cancer
             3. EGFR Mutation Therapy
       3. Germany
       4. France
       5. Spain
       6. Italy
       7. Russia
       8. Nordic
       9. Benelux
       10. Rest of Europe
12. Competitive Landscape, 2025
    1. Introduction
    2. Europe Afatinib Market Share Analysis, 2025 (%)
       1. Market Share Analysis, 2025
       2. Competition Ranking, 2025
       3. Key Developments & Growth Strategies
          1. Merger & Acquisition
          2. Product Launch
          3. Expansion
       4. Consolidated SWOT Analysis of Key Players
13. Company Profile
    1. Boehringer Ingelheim
       1. Business Overview
       2. Financial Data
       3. Key Product domains
       4. Recent Developments
    2. AstraZeneca
    3. Roche Holding AG
    4. Novartis AG
    5. Pfizer Inc.
    6. Merck KGaA
    7. Takeda Pharmaceutical Company
    8. Bristol-Myers Squibb
    9. Sanofi SA
    10. Eli Lilly and Company
    11. Bayer AG
    12. AbbVie Inc.
    13. Johnson & Johnson
    14. GlaxoSmithKline plc
    15. Amgen Inc.